TNBC
Axillary Surgery Deescalation Possible for Some After Neoadjuvant Chemo
Patients who are cN0 with HER2-positive or triple-negative breast cancer who receive full neoadjuvant chemotherapy ...
SEPTEMBER 1, 2021
Sacituzumab Shines in ASCENT TNBC Trial
The novel antibody–drug conjugate sacituzumab govitecan-hziy has provided an overall survival benefit over ...
APRIL 5, 2021
Keytruda Receives Triple-Negative Breast Cancer Indication
The FDA granted accelerated approval to pembrolizumab (Keytruda, Merck) in combination with chemotherapy for the ...
NOVEMBER 18, 2020
Olaparib Provides PFS Benefit in Pts With HER2-Negative Breast Cancer
Chicago—Relative to single-agent chemotherapies, olaparib delays time to both first and second progression in ...
JULY 12, 2017
Researchers Debate Role of
Pre-op Carboplatin in TNBC
San Antonio—Should clinicians routinely use carboplatin in the neoadjuvant setting for triple-negative breast ...
FEBRUARY 29, 2016
